Mealey's (January 30, 2018, 12:27 PM EST) -- WASHINGTON, D.C. — In a Jan. 26 cross-appellant brief Forest Laboratories LLC argued that although a Delaware federal judge properly determined that two claims of the patented atypical antipsychotic drug Saphris were not obvious, she erred in finding that several generic drug makers’ proposed products would not infringe (Forest Laboratories LLC v. Hikma Pharmaceuticals LLC, et al., No. 17-2369, Fed. Cir.)....